Characteristics of patients with primary Sjögren's syndrome
| Characteristics | Patients with primary Sjögren's syndrome (N=230) |
|---|---|
| Sex (female) | 219 (95.2) |
| Age (years) | 55.9 ± 13.9 |
| Disease duration (years) | 8.3 ± 5.6 |
| Ocular symptoms | 222 (96.5) |
| Oral symptoms | 219 (95.2) |
| Objective ocular involvement | 207 (90.0) |
| Objective oral involvement | 139 (60.4) |
| Positive salivary gland biopsy | 162/177 (91.5) |
| Autoantibodies to anti-SSA or anti-SSB | 184 (80.0) |
| Anti-SSA | 183 (79.6) |
| Anti-SSB | 115 (50.0) |
| Present or past systemic involvement | 140 (60.9) |
| Cutaneous | 54 (23.5) |
| Articular | 79 (34.3) |
| Muscular | 24 (10.4) |
| Pulmonary | 36 (15.7) |
| Central nervous system | 11 (4.8) |
| Peripheral nervous system | 28 (12.2) |
| B-cell proliferative disorder | 13 (5.7) |
| Present systemic involvement | 84 (36.5) |
| Present or past salivary gland swelling | 96 (41.7) |
| Present salivary gland swelling | 32 (13.9) |
| Present or past lachrymal gland swelling | 3 (1.3) |
| Current treatment | |
| Corticosteroids | 53 (23.0) |
| Hydroxychloroquine | 67 (29.1) |
| Azathioprine | 5 (2.2) |
| Methotrexate | 8 (3.5) |
| Rituximab | 3 (1.3) |
| Other immunosuppressant agent | 8 (3.5) |
| Pilocarpine | 35 (15.2) |
| Lachrymal substitute | 180 (78.3) |
| Saliva substitute | 71 (30.9) |
| Non-steroidal anti-inflammatory drug | 51 (22.2) |
| Analgesic | 47 (20.4) |
Results are reported as mean ± SD, or n (%).